A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test Design
Launched by VYNE THERAPEUTICS INC. · Aug 8, 2019
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female age 18 and older who was healthy
- • 2. Was of any Fitzpatrick Skin Type or race, providing the skin pigmentation allowed for discernment of erythema
- Exclusion Criteria:
- • -
About Vyne Therapeutics Inc.
Vyne Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with serious dermatological and autoimmune conditions. Leveraging its proprietary platform, Vyne aims to deliver novel treatments that address unmet medical needs through a combination of established and emerging therapeutic modalities. The company's commitment to advancing patient care is underscored by its rigorous clinical trial programs, which seek to validate the safety and efficacy of its therapeutic candidates. By fostering collaboration and maintaining a patient-centric approach, Vyne Therapeutics is dedicated to improving outcomes and enhancing the quality of life for individuals affected by challenging health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials